The FDA slaps a hold on uniQure's he­mo­phil­ia B gene ther­a­py as re­searchers ex­plore a case of liv­er can­cer in lat­est set­back for a boom­ing field

In the lat­est sam­pling of a set­back in the stum­ble-prone gene ther­a­py field, uniQure to­day an­nounced that the FDA has slapped a clin­i­cal hold on its work re­gard­ing their all-im­por­tant he­mo­phil­ia B pro­gram af­ter a pa­tient in the study de­vel­oped liv­er can­cer.

The stock $QURE, which hinges on the fate of uniQure’s piv­otal study for etranaco­gene deza­parvovec, slid more than 20% ahead of the bell on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER